Detection of 111In-oxine-labeled bone marrow stromal cells after intravenous or intralesional administration in chronic paraplegic rats

Haro, J. de; Zurita, Mercedes; Ayllón, L.; Vaquero, Jesús

doi:10.1016/j.neulet.2004.11.060

Cited by 39 publications

(25 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…administration. 85,86 In vitro predifferentiation of MSCs has also been attempted before transplantation into the injured spinal cord in an attempt to enhance repair. MSC-derived Schwann cells plus Matrigel, a synthetic scaffold material, were shown to promote axonal regeneration and functional recovery after complete transection of the adult rat spinal cord.…”

Section: Nonhuman Mscsmentioning

confidence: 99%

Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury

Parr

Tator

Keating

2007

Bone Marrow Transplant

408

316

View full text Add to dashboard Cite

Section: Nonhuman Mscsmentioning

confidence: 99%

Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury

Parr

Tator

Keating

2007

Bone Marrow Transplant

408

316

View full text Add to dashboard Cite

“…For a more in-depth discussion on this operaand skeletal tissue (24,25,33,58). It has been reported that these stem cells can also transdifferentiate into liver tional definition for stem cells we refer to a previous publication (82).…”

Section: Introductionmentioning

confidence: 99%

“…FGF-2 is known to positively affect tissue sparing nous administration (25). On the other hand, BMSCs (43,65) and promote neuronal survival and angiogenlabeled with iron oxide microbeads were detected using esis (65) following spinal cord injury.…”

mentioning

confidence: 99%

Bone Marrow Stromal Cells for Repair of the Spinal Cord: Towards Clinical Application

et al. 2006

View full text Add to dashboard Cite

Stem cells have been recognized and intensively studied for their potential use in restorative approaches for degenerative diseases and traumatic injuries. In the central nervous system (CNS), stem cell-based strategies have been proposed to replace lost neurons in degenerative diseases such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (Lou Gehrig's disease), or to replace lost oligodendrocytes in demyelinating diseases such as multiple sclerosis. Stem cells have also been implicated in repair of the adult spinal cord. An impact to the spinal cord results in immediate damage to tissue including blood vessels, causing loss of neurons, astrocytes, and oligodendrocytes. In time, more tissue nearby or away from the injury site is lost due to secondary injury. In case of relatively minor damage to the cord some return of function can be observed, but in most cases the neurological loss is permanent. This review will focus on in vitro and in vivo studies on the use of bone marrow stromal cells (BMSCs), a heterogeneous cell population that includes mesenchymal stem cells, for repair of the spinal cord in experimental injury models and their potential for human application. To optimally benefit from BMSCs for repair of the spinal cord it is imperative to develop in vitro techniques that will generate the desired cell type and/or a large enough number for in vivo transplantation approaches. We will also assess the potential and possible pitfalls for use of BMSCs in humans and ongoing clinical trials.

show abstract

“…de Haro et al [19] investigated radiopharmaceutical cell tracking 3 months after compressive spinal cord injury at T6-T8 level in rats. They injected 6 × 10 6 rat bone marrow derived mesenchymal stem cells (BM-MSCs) labeled with 111 In-oxine by the tail vein or by intralesional injection and performed whole-body planar imaging from 3 to 10 days.…”

Section: Published Preclinical Trialsmentioning

confidence: 99%

Radiopharmaceutical Stem Cell Tracking for Neurological Diseases

Rosado-de-Castro

Pimentel‐Coelho

Gutfilen

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

Although neurological ailments continue to be some of the main causes of disease burden in the world, current therapies such as pharmacological agents have limited potential in the restoration of neural functions. Cell therapies, firstly applied to treat different hematological diseases, are now being investigated in preclinical and clinical studies for neurological illnesses. However, the potential applications and mechanisms for such treatments are still poorly comprehended and are the focus of permanent research. In this setting, noninvasive in vivo imaging allows better understanding of several aspects of stem cell therapies. Amongst the various methods available, radioisotope cell labeling has become one of the most promising since it permits tracking of cells after injection by different routes to investigate their biodistribution. A significant increase in the number of studies utilizing this method has occurred in the last years. Here, we review the different radiopharmaceuticals, imaging techniques, and findings of the preclinical and clinical reports published up to now. Moreover, we discuss the limitations and future applications of radioisotope cell labeling in the field of cell transplantation for neurological diseases.

show abstract

Detection of 111In-oxine-labeled bone marrow stromal cells after intravenous or intralesional administration in chronic paraplegic rats

Cited by 39 publications

References 11 publications

Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury

Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury

Bone Marrow Stromal Cells for Repair of the Spinal Cord: Towards Clinical Application

Radiopharmaceutical Stem Cell Tracking for Neurological Diseases

Contact Info

Product

Resources

About